# PRECISE Phenotyping to Guide Therapies for Coronary Microvascular Dysfunction

> **NCT07533747** · PHASE3 · NOT_YET_RECRUITING · sponsor: **King's College London** · enrollment: 100 (estimated)

## Conditions studied

- Coronary Microvascular Dysfunction (CMD)

## Interventions

- **DRUG:** Empagliflozin 10mg OD

## Key facts

- **NCT ID:** NCT07533747
- **Lead sponsor:** King's College London
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2031-05
- **Final completion:** 2031-05
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07533747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07533747, "PRECISE Phenotyping to Guide Therapies for Coronary Microvascular Dysfunction". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07533747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*